Tag Archives: Imperial College London

British Heart Foundation The biggest independent funder of cardiovascular research in the UK, The British Heart Foundation plays a leading role in the fight against diseases of the heart and circulation by support of vital, pioneering research into their causes, prevention, diagnosis and treatment through research grants. It funds around £100 million of heart research every year. https://www.bhf.org.uk/research/information-for-researchers British Cardiovascular Society/BJCA The British Cardiovascular Society is a registered charity that aims to support and represents those working in cardiovascular care and research, by providing access to t

Promoting cardiovascular health is central to the national strategy to reduce premature mortality in our population. In this supplement, we offer a new approach to cardiovascular disease (CVD) prevention through the MyAction preventive cardiology programme, developed by Imperial College London. This nurse-led, multi-disciplinary, family-centred service embraces all patients with atherosclerotic disease – coronary heart disease, stroke and peripheral arterial disease – together with those identified through Health Checks to be at high risk of developing CVD in one community-based programme. In this supplement, we describe the studies that

Introduction Cardiovascular diseases (CVDs) are a single family of diseases with common antecedents requiring a holistic approach to prevention. This is the central theme of the new cardiovascular outcomes strategy for NHS England.1 Atherosclerosis is ubiquitous in the population, manifesting itself in different ways – acute coronary syndromes, transient cerebral ischaemia or claudication – but linked by a common pathology and underlying causes in terms of lifestyle and related risk factors. Many with one expression of this disease commonly suffer from another, and yet each is managed in silos of care through cardiology, stroke and vascul

Introduction The scientific evidence for cardiovascular (CVD) disease prevention is compelling but, as demonstrated by the EUROASPIRE and ASPIRE-2-PREVENT surveys, translating this evidence into effective patient care in the real-world in clinical practice is challenging.1,2 However, the same academic group have undertaken a number of trials and have shown that it is possible to implement national and international clinical guidelines and achieve the lifestyle, medical and therapeutic targets associated with reduced cardiovascular events and improved health outcomes.3-5 In recognising the need to bridge the implementation gap for prevention a